1. Home
  2. PGEN vs DCTH Comparison

PGEN vs DCTH Comparison

Compare PGEN & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Precigen Inc.

PGEN

Precigen Inc.

HOLD

Current Price

$4.43

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Logo Delcath Systems Inc.

DCTH

Delcath Systems Inc.

HOLD

Current Price

$10.06

Market Cap

350.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PGEN
DCTH
Founded
1998
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
350.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PGEN
DCTH
Price
$4.43
$10.06
Analyst Decision
Buy
Strong Buy
Analyst Count
5
5
Target Price
$7.67
$22.60
AVG Volume (30 Days)
3.9M
716.2K
Earning Date
11-13-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.03
Revenue
$6,309,000.00
$79,603,000.00
Revenue This Year
$342.78
$131.97
Revenue Next Year
$478.46
$38.84
P/E Ratio
N/A
$287.78
Revenue Growth
59.20
251.54
52 Week Low
$0.67
$8.12
52 Week High
$5.23
$18.23

Technical Indicators

Market Signals
Indicator
PGEN
DCTH
Relative Strength Index (RSI) 63.38 55.89
Support Level $3.64 $9.84
Resistance Level $3.75 $10.28
Average True Range (ATR) 0.26 0.45
MACD 0.08 0.04
Stochastic Oscillator 84.62 57.50

Price Performance

Historical Comparison
PGEN
DCTH

About PGEN Precigen Inc.

Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: